Johnson & Johnson plans $55B in United States investments
Aside from building four new plants, Johnson & Johnson said that it will expand several existing sites.
Pharmaceutical
-
Eli Lilly to spend $27B on four new manufacturing sites
The new manufacturing sites are expected to create create 3,000 pharmaceutical jobs and nearly 10,000 construction positions during the buildout.
Read More -
IBJ Podcast: The risks tariffs pose to Indiana’s manufacturing-heavy economy
President Trump wasted little time turning to economic policy once his second term began, imposing or threatening to impose a barrage of tariffs on many of Indiana’s trading partners.
Read More -
Trial shows Lilly’s Zepbound helps patients lose far more weight than competing drug
Eli Lilly and Co. said its weight-loss treatment Zepbound helped patients lose 47% more relative weight than competitor Novo Nordisk’s obesity treatment Wegovy in a head-to-head clinical trial.
Read More -
Why Lilly is pouring billions into LEAP
In recent years, the pharmaceutical manufacturer has seen dizzying growth in its pipeline for a wide range of diseases. And modes of drug delivery are becoming increasingly complex.
Read More
Articles
Purdue Pharma submits opioid lawsuit settlement plan, including up to $7B from Sacklers
Members of the Sackler family who own the OxyContin maker Purdue Pharma would hand over the company in the latest plan to settle thousands of lawsuits.
Zepbound raises profile of Lilly’s direct-to-consumer sales initiative
Indianapolis-based Eli Lilly and Co. launched LillyDirect a little more than a year ago and has been ramping up efforts to connect directly with consumers on the platform since.
Novo Nordisk cuts Wegovy prices, following similar move for Zepbound by Eli Lilly
Novo Nordisk’s new offering follows a direct-to-consumer model that Eli Lilly launched last year.
Study co-authored by IU researcher finds generic drugs made in India have more severe adverse events
The results showed that the number of severe adverse events for patients was 54.3% higher than that of drugs made in emerging economies.
Patients struggle with lack of consistent coverage for popular weight-loss drugs
Supplies of high-demand obesity treatments are improving, but that doesn’t mean they’re easier to get.
Lebanon planning board OKs design for Lilly Medicine Foundry at LEAP District
The foundry will give the pharmaceutical maker the ability to research new ways of producing medicines.
Trump casts psychiatric and weight-loss drugs as threats to children
President Donald Trump has instructed his administration to scrutinize the “threat” to children posed by antidepressants, stimulants and other common psychiatric drugs.
Could obesity drugs help with alcohol cravings? New study suggests potential.
The results add to evidence from animal studies and reports that people are finding the drugs helpful to manage cravings, not just for food, but also for tobacco and alcohol.
FDA approves non-opioid painkiller Journavx
The painkiller is the first novel pain drug to win government authorization in more than 20 years.
Purdue Pharma and owners to pay $7.4B in settlement over OxyContin’s toll
The deal represents an increase of more than $1 billion over a previous settlement deal that was rejected last year by the U.S. Supreme Court.
Sweeping review looks at effect of weight-loss drugs on 175 conditions
The research is the first to attempt to comprehensively investigate the impact—both good and bad—of the GLP-1 weight-loss drugs on the human body.
Indiana attorney general sues drug companies over EpiPen prices
The lawsuit alleges the price increases EpiPen, used to treat severe allergic reactions, prevented other similar medications to from going to market.
Lilly shares fall midday on lower fourth quarter revenue guidance
The company expects fourth-quarter revenue to be about $13.5 billion.
Lilly acquires Scorpion Therapeutics in deal worth up to $2.5B
The Indianapolis-based drugmaker will acquire Scorpion’s STX-478, a once-daily oral treatment in early trials for breast cancer and other advanced solid tumors.
Lilly sees new weight-loss pill approval in early 2026, CEO says
Pills would be more convenient for patients and also easier to manufacture at large scale than other top weight-loss drugs, which require , CEO Dave Ricks said.
U.S. ‘notorious markets’ report warns of risks from online pharmacies
The report says 96% of online pharmacies were found to be violating the law, many operating without a license and selling medicines without prescriptions and safety warnings.
FDA set to phase out leading decongestant in many cold medicines
Phenylephrine is used in popular versions of Sudafed, Dayquil and other medications, but experts have long questioned its effectiveness.
FDA approves Lilly’s Zepbound for obstructive sleep apnea
Lilly’s stock was up slightly in after-hours trading.
Lilly stock caught up in wave of uncertainty
After a stunning 703% run-up in price over the past five years, shares of Eli Lilly and Co. have been on a roller-coaster ride since September.